OPRM1/MOP (Mu Opioid Receptor) Drug Discovery Landscape & Assay Solutions
- By admin
- 24 Aug 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Pain Management & Opioid Use Disorder Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for OPRM1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full-Length) | OPRM1 Full-Length Lentivirus / Stable Cell Line HEK293 expressed, preserves native glycosylation and conformation. Sequence Verified. |
View OPRM1 Products |
| Antigen (ECD-Fc) | OPRM1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View OPRM1 Products |
| Gene Delivery | OPRM1 Promise-ORF Lentiviral Particles Codon-optimized for high expression; generates stable lines for pathway assays. |
View OPRM1 Products |
| Benchmark Ab | Anti-OPRM1 Reference Antibody (Sequence of Uxefumab analog / Benchmark Drug) Recombinant positive control for binding and internalization. |
View OPRM1 Products |
| Validator | OPRM1 siRNA Set For knockdown verification and specificity controls. |
View OPRM1 Products |
| Related Target A | OPRD1 (Delta Opioid Receptor) Synergistic pathway; heterodimerization screening; selectivity panel. |
View OPRD1 Products |
| Related Target B | OPRK1 (Kappa Opioid Receptor) Off-target liability and selectivity counter-screening. |
View OPRK1 Products |
Critical Assay Challenges & Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformational Integrity | Lentivirus-mediated stable cell lines in HEK293 preserve native folding and signaling competence for OPRM1. |
| Biased Signaling Discrimination | Compatible with GTPγS, cAMP, and β-arrestin recruitment assays using sequence-verified receptors. |
| Cross-species Translation | Human/Mouse/Cyno ortholog OPRM1 stable cell lines available for translational bridging. |
| Selectivity & Off-target Toxicity | OPRD1 and OPRK1 panel available for rigorous selectivity screening against subfamily off-target liabilities. |
| Assay Specificity Control | Validated siRNA included for target-specificity confirmation (false positive reduction). |
| Lack of Positive Controls | Clinical Benchmark Antibodies (Biosimilars) included to ensure assay reliability. |
Live OPRM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
"The race for next-generation OPRM1 therapeutics is shifting from traditional agonists to G-protein biased agonists and peripherally restricted compounds. As the field addresses the respiratory depression and addiction liabilities of first-generation opioids, the demand for sophisticated cell-based assays that can discriminate between G-protein and β-arrestin signaling has intensified."
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Biased Agonist (Small Mol) | Trevena, Cerevel (AbbVie), Alkermes | Acute/Chronic Pain | Biased Signaling Assays (GTPγS, cAMP, β-arrestin) – need stable cell lines |
| Peripherally Restricted Agonist | Nektar, Lexicon | Chronic Pain (Non-addictive) | Blood-Brain Barrier Permeability Models; Peripheral receptor access assays |
| Antagonist/Partial Agonist | Indivior, Alkermes | Opioid Use Disorder (OUD) | Receptor occupancy assays; Competitive binding with high purity standards |
| Allosteric Modulator | Multiple Biotechs | Pain, Itch | Orthosteric/allosteric site selectivity; PAM/NAM functional assays |
| Monoclonal Antibody | Emerging Biotechs | Opioid Use Disorder | Receptor Binding (Need high-purity ECD) |
| Gene Therapy | Academic Spin-offs | Severe Chronic Pain | Delivery Validation (Need precise ORF constructs) |